Business · 09/10/2026
EMA Approves Modification to Paediatric Investigation Plan for Stelara and Ustekinumab
The European Medicines Agency (EMA) has made a decision on a Paediatric Investigation Plan (PIP) for Stelara and ustekinumab, a treatment for musculoskeletal and connective tissue disorders. The decision relates to a modification of an existing PIP application.